Additionally, in our prior work that established the role of FOXC2 in carcinoma progression through the induction of EMT, we did not see β-catenin levels significantly change as a result of FOXC2 expression [9], an observation supported in PDAC [20]. The gene discussed is FOXC2; the disease is carcinoma.